Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
| Small Cap
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
N/A
Industry Median
N/A
Market Cap Median
N/A
P/B RATIO
N/A
Industry Median
N/A
Market Cap Median
N/A
P/S RATIO
N/A
Industry Median
N/A
Market Cap Median
N/A
Others
PEG RATIO
N/A
EV/EBITDA RATIO
N/A
Revenue GrowthAverageEBITDA GrowthAverageEPS GrowthAverageRevenue Growth
EBITDA Growth
EPS Growth
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 2 | SMS Lifesciences India Ltd | 6.59 | 22.25 | Undervalued | 45.00 | 58.80 | 19.00 |
| 3 | Infinium Pharmachem Ltd | 6.42 | 33.97 | Neutral | 22.00 | 6.43 | 14.00 |
| 4 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 60.35 | Neutral | 7.00 | 1.40 | 4.00 |
| 5 | Albert David Ltd | 5.63 | -333.98 | Neutral | 5.00 | -2.62 | -1.00 |
| 6 | BPL Ltd | 5.46 | -28.58 | Neutral | -4.82 | -1.69 | -8.55 |
| 7 | Zim Laboratories Ltd | 5.41 | 108.20 | Neutral | 30.00 | 1.11 | 6.00 |
| 8 | Quest Laboratories Ltd | 5.27 | 9.34 | Neutral | 18.00 | 9.16 | 15.00 |
| 9 | Sotac Pharmaceuticals Ltd | 5.27 | 17.25 | Neutral | 18.00 | 4.45 | 6.00 |
| 10 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 11 | Krebs Biochemicals & Industries Ltd | 4.16 | -4.36 | Highly Undervalued | -4.00 | -7.85 | -4.00 |
| 12 | Nectar Lifescience Ltd | 3.83 | -0.80 | Neutral | -59.00 | -2.95 | -293.00 |
| 13 | PANCHSHEEL | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Lyka Labs Ltd is an Indian pharmaceutical company engaged in the manufacturing and marketing of a diverse range of pharmaceutical formulations. Its product portfolio spans injectables, tablets, liquids, and dry syrups, addressing various therapeutic areas. The company serves both the domestic Indian market and actively exports to international markets.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Lyka Labs Ltd's P/E ratio (TTM) is N/A, compared to the industry median of 38.50 and large cap median of 37.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Lyka Labs Ltd's P/B ratio is N/A, compared to the industry median of 4.50 and large cap median of N/A.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Lyka Labs Ltd's P/S ratio is 2.11, compared to the industry median of 3 and large cap median of N/A.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Lyka Labs Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Lyka Labs Ltd's EV/EBITDA ratio is 20.60.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Lyka Labs Ltd's ROE is N/A.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Lyka Labs Ltd's ROA is N/A.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Lyka Labs Ltd's ROCE is N/A.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Lyka Labs Ltd's operating margin is N/A.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Lyka Labs Ltd's net margin is N/A.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Lyka Labs Ltd's current ratio is N/A.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Lyka Labs Ltd's debt-to-equity ratio is N/A.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Lyka Labs Ltd's interest coverage ratio is N/A.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Lyka Labs Ltd's DPS is ₹0.50.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Lyka Labs Ltd's EPS is N/A.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹N/A. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1976
Headquarters: Mumbai, Maharashtra
Core Offerings: Injectables, Tablets, Liquids, Veterinary Products, Oncology Formulations
Stock Listing: NSE (LYKALABS), BSE (500259)
Promoter: Patel Group
Lyka Labs Ltd was incorporated in 1976 and commenced commercial production of bulk drugs and formulations in 1981. Over the decades, the company has expanded its product portfolio to cover various therapeutic segments and dosage forms, with a growing focus on specialized products including injectables and oncology. Today, it manufactures and markets pharmaceutical formulations in India and exports to over 40 countries.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Formulations | 100% | Operating Profit |
Mr. N. I. Patel - Chairman & Managing Director. A veteran with significant experience in the pharmaceutical industry, he has been instrumental in guiding the company's growth and strategic direction.
Lyka Healthcare Limited (Wholly Owned Subsidiary)
Lyka Exports Limited (Wholly Owned Subsidiary)
Lyka B.V. (Netherlands)
The company completed a Qualified Institutional Placement (QIP) in 2022. No other major recent corporate actions (like bonus issues, rights issues, or significant M&A) on record.
The Lyka Labs Ltd share price today is ₹N/A on NSE (LYKALABS), as of 26 Sept 2026.
As of 26 Sept 2026, Lyka Labs Ltd share price is ₹N/A, with previous close ₹N/A. Today's range is ₹N/A to ₹N/A. The 52-week range is ₹N/A to ₹N/A.
As of today, Lyka Labs Ltd's market cap is ₹N/A crore (Small Cap).
Lyka Labs Ltd's current P/E ratio is N/A, compared to the Financial Services sector average of 37.
Lyka Labs Ltd's current P/B ratio is N/A.
Lyka Labs Ltd's current dividend yield is N/A. Last dividend of ₹0.50 per share was declared on 22-Sep-2023.
Lyka Labs Ltd's EPS (TTM) is ₹N/A.
Lyka Labs Ltd is an Indian pharmaceutical company engaged in the manufacturing and marketing of a diverse range of pharmaceutical formulations. Its product portfolio spans injectables, tablets, liquids, and dry syrups, addressing various therapeutic areas. The company serves both the domestic Indian market and actively exports to international markets.
Lyka Labs Ltd is promoted by Patel Group, holding N/A as of 26 Sept 2026.
Lyka Labs Ltd is listed on NSE (LYKALABS) and BSE (500259). Its next quarterly results are expected on August 2024 (for Q1 FY25 results).
Capital Efficiency & Returns
Shareholding & Ownership Structure
